Document Detail


HER2 targeted therapies for cancer and the gastrointestinal tract.
MedLine Citation:
PMID:  19519356     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
HER2 (v-erb-b2 erythroblastic leukemia viral oncogene) is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. Since the discovery of a role for HER2 and other EGF receptors in the development and progression of cancer, they have become targets for a number of targeted anti-cancer drugs. These drugs have proven to be effective in treating and managing a range of cancers, however, recent observations in the clinic have suggested that their administration causes many toxicities, including gastrointestinal toxicity. Drugs with HER2 inhibitory activity fall into two categories; the monoclonal antibodies and small molecule tyrosine kinase inhibitors. Both of these drug classes have been shown to induce symptoms consistent with mucositis development; including nausea and vomiting, diarrhoea and abdominal pain. However, to date, limited studies have been carried out to justify the source of these toxicities. This review summarizes our current knowledge of the toxicities associated with commonly used HER2 targeted therapy drugs, the role of HER2 in cancer and the healthy gastrointestinal tract and the possible mechanisms by which drugs with HER2 inhibitory activity can induce gastrointestinal damage and possibly mucositis in patients.
Authors:
Noor Al-Dasooqi; Rachel Gibson; Joanne Bowen; Dorothy Keefe
Related Documents :
21888766 - The bacterial redox signaller pyocyanin as an antiplasmodial agent: comparisons with it...
19117686 - Microtubule dynamics as a target in oncology.
17263126 - Novel targets and therapies for metastatic renal cell carcinoma.
15597396 - A rational approach to maximize success rate in target discovery.
24146506 - Analysis on 113 cases of adverse reactions caused by β-lactam antibiotics.
15777266 - Novel antitumor agents: marine sponge alkaloids, their synthetic analogs and derivatives.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current drug targets     Volume:  10     ISSN:  1873-5592     ISO Abbreviation:  Curr Drug Targets     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-12     Completed Date:  2009-09-02     Revised Date:  2012-10-12    
Medline Journal Info:
Nlm Unique ID:  100960531     Medline TA:  Curr Drug Targets     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  537-42     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Adelaide, Adelaide, Australia. noor.abdulghafour@adelaide.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal / adverse effects,  immunology,  pharmacology,  therapeutic use
Antineoplastic Agents / adverse effects*,  pharmacology,  therapeutic use
Gastrointestinal Tract / drug effects*,  metabolism
Humans
Mucositis / chemically induced
Neoplasms / drug therapy*,  metabolism*
Protein Kinase Inhibitors / adverse effects,  pharmacology,  therapeutic use
Receptor, erbB-2 / antagonists & inhibitors*,  immunology,  metabolism
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Protein Kinase Inhibitors; EC 2.7.10.1/ERBB2 protein, human; EC 2.7.10.1/Receptor, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL.
Next Document:  The role of proteomics in osteoarthritis pathogenesis research.